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AT- a,-antitrypsin or a,-antiprotease inhibitor 
Suc-AAPF-pNA- N-Succinyl-Alanine-Alanine-Proline-Phenylalanine-p- 
nitroanilide 
L-BAPNA- Na-Benzoyl- L-arginine 4-nitroanilide hydrochloride 
HNE- Human neutrophil elastase 
PPE- porcine pancreatic elastase 





SI- Stoichiometry of Inhibition 
TBG- Thyroxine binding globulin 
PEDF- Pigment epithelium derived factor 
PAI-1- plasminogen activator inhibitor-I 
PAI-2- plasminogen activator inhibitor-2 
ANS- 2,6-Anilinonapthalenesulfonic Acid 
TNS- 6-(p-Toluidino)-2-napthalenesulfonic acid 
Bis-ANS- 4,4'-Dianilino-I ,I '-binapthyl-5,5'-disulfonic acid 
NBD- nitrobenzoxadiazole 
CBG- corticosteroid binding globulin 
OVUS- Ovine uterine serpin 
PI1 0- Bomapin 
tPa- tissue plasminogen activator 
uPa- urokinase-type plasminogen activator 
TBS- 20 mM Tris-HCI buffer, pH 7.5, containing 100 mM NaCl 
Abstract 
SMALL MOLECULES BINDING TO SERPINS 
By Junaid Haider Afridi, M.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of 
Master of Science at Virginia Commonwealth University 
Virginia Commonwealth University, 2006 
Dr. Umesh Desai, Associate Professor, Medicinal Chemistry 
Serpins are a unique breed of proteins due to their enzymatic 
mechanism. Two systems were closely monitored during fluorescent binding 
studies, the ACT-CHY along with the AT:TRY interaction. Four different 
conformational variants of each system were studied including the native, 
cleaved, latent and complex forms. Three different fluorescent dyes were used 
to identify the conformations including ANS, TNS, and bis-ANS. SI studies and 
protease assays utilizing both Suc-AAPF-pNA and L-BAPNA were instrumental 
in determining conformations along with gel electrophoresis studies. The 
hydrophobic dyes bound to the different serpins with varying KD and AFmax 
due to structural variations among the conformers and the complex. Both TNS 
and bis-ANS gave higher AFmax values than ANS. Bis-ANS gave significantly 
higher AFmax values for the ACT:CHY than the other conformations, while also 
exhibiting relatively low KD value. KD values for the bis-ANS complexes are 
relatively low when compared to other fluorophores. Bis-ANS is more specific 
for the AT system than either TNS or ANS. Bis-ANS displays a AFmax of 36 
fold for the ACT:CHY complex, while TNS displays a 27 fold increase for 
AT:TRY system. Modulation studies using bis-ANS to alter the kinetics of latent 
ACT formation proved unsuccessful, suggesting that fluorescent dyes have 
little, if any effect on serpin variant formation. 
Chapter 1 : Introduction 
Serpins were first identified as a family of molecules by Hunt and 
coworkers in 1980, after noticing a primary sequence identity of -30% among 
human al-antitrypsin, human antithrombin, and chicken egg white ovalbumin.ls2 
Later, antitrypsin and antithrombin, along with a handful of other similar 
molecules were found to inhibit proteases containing serine as a catalytic 
residue, and hence the name ~ i n e  potease bhibitors (serpins). Many other 
proteins have now been added to this list, which continues to grow, although 
many are not inhibitors of serine proteases3 
Today nearly 500 serpins across all species are known to exist. All 
proteins classified as serpins have a common tertiary structural fold consisting of 
3 P-sheets and 8-9 a-helices. Outside of these conserved structural domains the 
sequence variability is quite large. Most serpins have a molecular weight ranging 
from 40 to about 65 kDa, while the largest known serpin, C1 inhibitor, has a 
molecular weight of about 105 k ~ a . ~  Some of the unusual serpins include 
cysteine protease inhibitors, such as squamos cell carcinoma antigen I, and 
noninhibitory serpins, such as egg white ovalbumin and angioten~in.~ 
The 500 or so serpins have been classified by the HUGO Gene 
Nomenclature Committee and placed into sixteen different serpin clades based 
on their phylogenetic associations. The clades are designated by letters ranging 
from A through P . ~  
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Figure 1: Taken from ~ettins.' Four stereo views of a,-antitrypsin, a prototype serpin molecule. The RCL 
is known as the reactive center loop, and can be seen at the top of the molecule while h denotes a helix, 
and s denotes p sheet. The important residues are the RCL in yellow, and p sheet C in red. 
Human serpins are located on 10 different chromosomes, although a 
majority of them are located in three clusters. It is interesting to note that within 
each cluster the serpins belong to the same clade and one explanation for this 
phenomenon is that many serpins are a result of gene duplication. 
Serpins are involved in many important, highly regulated physiological 
processes including blood coagulation, fibrinolysis, apoptosis, hypertension, 
hormone transport and inflammation. 9, 10, 11 In humans 34 serpins have been 
identified to date and most of them have been well studied and characterized 
(See Table 1). al-Proteinase inhibitor also called antitrypsin, is quite abundant in 
our body at normal physiological levels of about 1-2 mg/mL and increases during 
inf~ammation.~ Its main function is to inhibit elastase, which is secreted by 
human neutrophils during periods of inflammation. Antitrypsin plays an important 
role in human physiology due to its involvement in multiple disease states and 
deficiencies. Notably, scientists have been able to link the deficiency of al- 
antitrypsin to emphysema. Emphysema occurs as a result of the inability to 
control inflammation, and this situation is further exacerbated by smoking, which 
leads to oxidation of the PI methionine to sulfoxide, making the al-antitrypsin 
molecule nearly 2000 times less reactive than the thioether.12 
Native Structure 
The native, or active conformations of serpins have 3 P-sheets along with 
9 a-helices, which corresponds to residues 21-389 of al-antitrypsin (Figure 3). 
The three P-sheets contain fourteen strands in all, with P sheet A composed of 5 
strands and is the largest as it extends from one end of the serpin skeleton to the 
other. P-sheet B contains six strands and P-sheet C has three strands. A unique 
property of the third and fifth strands of P-sheet A is that they are parallel strands, 
whereas the rest of the strands in p sheets are antiparalleL7 The native structure 
also is composed of a reactive center loop (RCL) which is exposed and links P 
sheet C to p sheet A. The RCL contains anywhere from 22 to 27 amino acid 
residues labeled P9' to P17, where the PI '-PI bond denotes the scissile bond. 
The residues of the RCL define the specificity of serpins, as this area interacts 
with the potential substrate binding sites of the target protease. The N-terminal 
(PI-PI 7) of the RCL must be at least 17 residues long to permit full insertion of 
residues during formation of cleaved and latent forms. 
Cleaved Structure 
The first structure that was crystallized was of cleaved al-antitrypsin by 
Huber et al in 1984.13 The researchers were actually attempting to crystallize the 
complexed form of antitrypsin with elastase, but in the process the antitrypsin 
molecule was cleaved by elastase and the resulting structure was that of cleaved 
antitrypsin (Figure 2). This cleaved antitrypsin showed strand insertion of the 
RCL of the antitrypsin into P sheet A between strands 3 and 5. Due to this 
insertion the ends of what was the scissile bond at PI were moved about 70 A 
apart. This change affects the rest of the serpin molecule, mostly by rearranging 
of underlying helices.14 The process of conversion is quite favorable, resulting in 
a structure that is stable to denaturation up to about 120°C for the cleaved 
variant, while studies show that native serpin is stable to about 60°C. 
Calorimetric measurements for heat released on insertion of the RCL in p-sheet 
A, and AH has a large value of about 60 kcal/mol.15 
Latent Structure 
The latent form of a,-antitrypsin was deduced by Tucker et al. in 1995 
simply by placing active native al-antitrypsin in a solu.tion of citrate at elevated 
temperatures for about 12 hours.16 This variant displayed some similarities to the 
cleaved form in that the RCL had been inserted in p sheet A as displayed 
through crystal structures (Figures 1 and 3), although residues of the RCL were 
still intact in the case of the latent form (Figure 4). These residues provide the 
return loop towards the top of the molecule in the latent form, while in the cleaved 
form the C-terminal detached residues make up strand 1 of P sheet C. 
Formation of the latent structure is favorable for many serpins including al- 
antitrypsin due to its lower energy conformation. This is partially a result of p 
sheet insertion, although this variant has been shown to be less stable than the 
cleaved form, and scientists suggest that this is due to the loss in stability by 
removing a strand from p sheet C. 
Figure 1: Cleaved ~nt ich~rnotr~psin~ '  
Figure 2: Native Antitrypsin18 
- 
Figure 3: Latent PAI-1'' 
Figure 4: Antitrypsin-Trypsin 
r**C) 
Serpin-Protease Complex 
Complex formation of serpins had proven elusive to researchers and in 
1995, Wright suggested that the RCL of serpins inserts into P sheet A, while s,till 
preserving the covalent bond to the protease, which results in a serpin:protease 
complex with protease at the distal end from the previously uncleaved reactive 
site loop.22 This suggested a complex structure similar to the cleaved structure, 
except that the protease remains tightly bound in an irreversible complex. In 
2000, Huntington had solved the mystery of the complex structure, and the 
resulting structure gives insight to how and why the irreversible complex is 
formed (Figure 5).' The reaction between serpins and proteases results in a 
33% loss in the overall structure for the protease molecule, destabilizing it, while 
complex formation actually stabilizes the serpin, although a recent study 
questions this claim. The catalytic triad of the protease in this case is altered 
such that the serine 195 in trypsin is bound to Met358 of a,-antitrypsin, causing 
the active site area to change conformation, making the catalytic triad less 
effective in hydrolyzing the acyl bound protease. This conformational change 
does not disrupt the hydrogen bond between His57 and Aspl02, but it does raise 
the pKa of His57 by about one pH unit.g This conformational trap prevents 
catalytic deacylation of the protease, effectively creating a suicide inhibition. This 
was quite an important discovery because it established a relationship between 
the conformational change in serpins and reaction with proteinase. Also, 
reaction with the proteinase causes a dramatic and unique change, one in which 
the internal skeleton of the serpin is altered and the proteinase is translocated to 
the opposite pole of the serpin molecule as evidenced by the cleaved strand 
located at bottom of ~ e r ~ i n . ~ ~  Furthermore, it has also been reported that along 
with changes in conformation of protease, the hydrolysis of the acyl-enzyme 
bond is also partially dependent upon the length of the RCL of the serpin. 
Kinetic Mechanism of Serpin Protease Reaction 
The serpin:proteinase reaction occurs in several steps to form either the 
irreversible inhibitor complex or the cleaved serpin and active enzyme. The 5 
steps for serpin reaction as a substrate are: 1) formation of the intitial 
noncovalent Michaelis complex; 2) active site serine of protease reacting with the 
P I  peptide of the serpin forming a tetrahedral intermediate; 3) the peptide bond 
cleaved resulting in a covalent acyl ester intermediate; 4) formation of the second 
tetrahedral intermediate through addition of water; 5) substrate leaves the active 
site area. Formation of cleaved serpin occurs as a result of serpins following 
steps 1 to 5 through completion of reaction, while formation of the irreversible 
serpin:protease complex follows steps 1 through 3 which may be seen kinetically 
in Figure 7 and chemically in Figure 8. 
Figure 7: Kinetic Mechanism of ~ e r p i n s ~ ~  
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Figure 8: Standard Scheme for serine-protease hydrolysis, shows substrate in an extended conformation in 
a binding cleft, and key protease residues and interactions. Ser195 of the serine protease is activated by 
His57 for nucleophilic attack at the carbonyl group of the scissile bond. (a) Acylation proceeds via a 
tetrahedral intermediate, which is stabilized by favorable interactions between the negatively charged 
substrate oxygen and amino groups of the protease main chain. (b) Deacylation proceeds via the addition 
of activated water. P I  and PI '  denote the side chains of residues at the sci:le bond; R and R' indicate the 
upstream and downstream fragments, respectively. Taken from Engh et al. 
The first pathway describes the formation of the cleaved substrate serpin 
and has an overall rate constant of k3. The second pathway describes the acyl 
intermediate becoming blocked by ineffectiveness of proteinase to complete the 
proteolysis reaction, and this occurs before step 4. As a result of the loop 
insertion induced conformational change within the serpin and the resulting 
distortion of the proteinase active site. The overall rate constant for 
serpin:protease complex formation is described by kq. Once inactivation of 
proteinase as a result of complete loop insertion of the RCL has occurred, this 
results in the proteinase being unable to undergo deacylation. As a result, the 
serpin is bound irreversibly to the proteinase following the substrate suicide 
kinetic pathway, kq. 
The effectiveness of this reaction is displayed by measuring the k5 value of 
the complex conversion to cleaved serpin. The k5 value represents deacylation 
of the serpin:proteinase and studies show that k5 is at least 5-7 orders of 
magnitude less than k3. The relative proportion of the acyl enzyme complex 
which is converted to either cleaved serpin or irreversible suicide complex 
depends on the relationship between k3 and kq. If k3 >> kq, the major end product 
is free enzyme and cleaved serpin, while kq >> k3 gives an irreversible serpin: 
proteinase complex as major end product. The SI is given by SI = (k3 + kq)/kq, 
and where kq is much greater than kg then the SI is -1. The key to forming the 
complex is to have loop insertion occur before the bond is hydrolyzed. Different 
factors lead to the variation in this ratio which favors one form over another. 
Serpin-Ligand Interactions 
Determinin~ the Interaction 
The ability of serpins to bind to a variety of ligands is useful in studying 
ways to alter serpin activity. Since serpins play vital roles in our biological 
systems, studying serpin ligand interactions becomes an invaluable tool in 
helping to discover serpins' role in the body, and how altering their activity affects 
a biological system. The binding of serpins to proteinases in order to inhibit them 
is the most common serpin interaction studied, and in many cases this interaction 
may be influenced by a cofactor such as heparin. Serpins in this group include 
antithrombin, heparin cofactor II, protein C inhibitor, plasminogen-activator 
inhibitor-I (PAI-I), protease nexin-I, and kallistatin. Protein ligands bound to 
serpins may also have an effect on activity and such is the case with PAI-1 
binding to v i t r~nec t in .~~  some serpins depend on ligands in order to carry out 
their function, such as the transport of thyroxine by thyroxine binding globulin 
(TBG) or the inhibition of blood vessel growth by pigment epithelium derived 
factor (PEDF). 
There are many different techniques to identify and analyze ligand-serpin 
interactions such as yeast 2-hybrid analysis, spectroscopic techniques, kinetic 
methods, surface plasmon resonance, and affinity chromatography. The 
mapping of binding sites on serpins has been studied using chemical 
modification, site directed mutagenesis, epitope mapping, and crystallography 
methods.27 No one method is universally better than the other and many serpin- 
ligand interactions have been discovered by multiple techniques to verify the 
results. 
Genetic mapping has allowed us to determine the structure of serpin 
molecules and their target proteinases. In this case, A simple method to verify 
whether a ligand may inhibit a serpin is to simply incubate the serpin with ligand, 
and to measure for activity of the serpin. If serpin activity has been affected, then 
it is presumed that ligand is interacting with it. Determining a potential ligand 
may be done using many methods. For those serpin molecules which have been 
known to bind to non-proteinase ligands for biological reasons, designing and 
synthesizing novel ligands may be aided by ligand structure. Currently, there is 
much work being done to improve upon heparin activity creating analogues of its 
pentasaccharide substructure. 
Gel filtration chromatography has proven useful in discovering natural 
ligands of a serpin. There are many different types of columns, such as size- 
exclusion, and ion-pair, and different techniques used such as thin layer, and 
affinity chromatography. This method requires the passage of a biological fluid 
such as blood plasma thru a column, to which the natural serpin is bound. This 
elution time is compared with that of free serpin through the column, known as 
resolution. If there is difference in elution time, it suggests that the serpin is 
complexed. This is the method which led to the known association between PAI- 
1 with ~ i t r onec t i n .~~  
Once a potential ligand has been identified, confirmation of interaction 
must be determined. Solid phase binding methods may be useful for this 
purpose. Here, once a potential ligand is identified, it is then immobilized onto a 
matrix, which is then packed onto a column. A solution containing the target 
serpin is then eluted through the column. This particular method has been used 
to establish the binding of several serpins to glycosaminoglycans such as 
heparin. Examples include antithrombin, heparin cofactor II, protease nexin-I, 
protein C inhibitor, PAI-I , and kal~istatin.~. The next step would be to measure 
the affinity of the ligand-serpin interaction. There are several techniques which 
have proved useful in determining this affinity. One popular technique is solid- 
phase binding methods. One of the species is immobilized on a solid support, 
while the other species is added in solution. Once equilibrium is reached, the 
solid phase is separated from the solution phase and washed. The amount of 
species bound to the immobilized species may then be quantified. This method 
has been proven useful for verifying high affinity interactions of a ligand with a 
serpin, such as protease nexin 1 and C1-inhibitor with collagen. 29"1 This method 
is simple, but the major disadvantage is that the immobilized species may be 
heterogeneous with respect to attachment to the surface. In order to overcome 
this obstacle, competitive binding approaches may be used. Here the approach 
is similar to the previous method except that one species is bound to a known 
ligand, and this complex is progressively dissociated by adding increasing 
concentrations of the partner species. The difference in total serpin 
concentration required to achieve equivalent saturation of the immobilized ligand 
in the absence and presence of the competitor ligand provides an accurate 
measure of concentration of the solution serpin-ligand complex independent of 
the nature of immobilized serpin-ligand interaction. 
Quantitatinq the Interaction 
For those situations where one may not be able to immobilize a species 
onto solid phase, other techniques exist to quantitatively measure the serpin- 
ligand interactions. One such technique is the use of intrinsic or extrinsic 
spectroscopic probes to study the interaction. Intrinsic probes are usually found 
within the aromatic residues of the serpin, which have characteristic near UV 
absorbance and fluorescence properties, which may be altered as a result of 
ligand binding. Tryptophan fluorescence has been particularly useful for intrinsic 
fluorescence measurements. Antithrombin high affinity interactions in the 
concentration range of 10-20 nM have been studied using fluorescence. It also 
has proved useful in detecting other serpin-ligand interactions as well. For 
example, kallistatin, a serpin expressed in endothelial and smooth muscle cells of 
blood vessels, undergoes a 50% enhancement in intrinsic fluorescence upon 
binding to heparin.32 Where the protein ligand possesses intrinsic fluorescence, 
a difference between the fluorescence of an equimolar mixture of serpin and 
ligand and the summed fluorescence of free protein and ligand may help indicate 
whether the serpin-ligand interaction perturbs the intrinsic fluorescence of one of 
the interacting components.33 
In many cases, the fluorescence energy of the serpin is not affected by the 
binding of a ligand, and hence an extrinsic fluorophore may be used. These 
extrinsic fluorophores bind noncovalently to the serpin, which changes the 
fluorescent characteristics of the fluorophore. Examples of the use of 
noncovalent fluorescent probes to study serpin-ligand interactions include TNS, 
ANS, and bis-ANS. ANS has been studied in the particular case of binding to the 
hormone pocket of the serpin, TBG, with nearly a four fold increase in its 
fluorescence emission. 349 35 Here, binding of hormone displaces the fluorophore 
and this in turn causes a decrease in fluorescence, a useful technique for 
quantifying the affinity of the hormone for the serpin. When conducting binding 
studies with a fluorophore probe, it is important to assess whether the labeling 
has affected the interaction. This can be done by competitive binding studies in 
which the unlabeled serpin or ligand is used to compete with the labeled 
component for binding the species. This was done with the binding of S195A 
tPA or anhydrotrypsin to recombinant PAI-1 labeled at the P I '  reactive center 
loop residue with the fluorophore, NBD, through an engineered P I '  ~ ~ s t e i n e . ~ ~  
Binding of the labeled PAI-1 to inactive proteases was shown to be weaker then 
was the unlabeled wild-type PAI-1, by studying the fluorescence changes linked 
to the displacement of the labeled PAI-1 from its complex with proteinases by 
unlabeled ~ e r p i n . ~ ~  ANS, TNS, and bis-ANS have played an important role in 
determining structural changes in the serpin as a result of binding to the ligand, 
where a ligand bound to serpin causes a change in serpin structure, and this 
translates into a change in fluorescence. Fluorophores may be used to measure 
potential binding sites on serpin molecules, because of their small structure, 
propensity to bind to hydrophobic pockets and the change in fluorescence which 
may be easily detected. As of the present time, binding studies with these small 
organic ligands have only been carried out on structural variations of PAI-1 .27 
This interaction may be further studied through the variability in structure and 
function in serpins to perhaps elucidate potential ligands, which is the focus of 
this dissertation. 
Figure 9: Organic Fluorophores-ANS, TNS, bis-ANS 
2'6-Anilinonapthalenesulfonic Acid (ANS) 6-(p-Toluidino)-2-napthalenesulfonic acid (TNS) 
I 
OH 
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Figure 10: Heparin pentasaccharide bound to antithrombin dimer40 
The interaction between serpins and ligands from a mechanistic point of 
view gives a better look at the potential effect of ligand binding. Because serpins 
go through a branched pathway suicide substrate mechanism, which permits 
formation of either the cleaved non-complexed or cleaved complexed form, the 
effect of the ligand on serpin function may be determined. This can be done by 
titrating a fixed concentration of enzyme with increasing concentrations of serpin 
in the presence and absence of ligand. After this reaction has reached 
completion, the residual enzyme activity is determined by monitoring the initial 
rate of hydrolysis utilizing a suitable chromogenic substrate. 4 0 ~ 4 1  -rhe 
stoichiometry can then be determined from the x-intercept of a plot of residual 
activity vs. the ratio of serpinlprotease concentration. If the ligand has affected 
the serpin pathway, then either or both rate constants of mechanistic pathways 
will be altered. This pattern was seen for heparin reaction in the presence of 
antithrombin, thrombin and factor Xa. 42v 43 Measurements of the change in Kobs 
can help to provide a means of measuring the affinity of serpin-ligand interaction. 
Measuring change in kbs for serpin:protease as a function of ligand 
concentration should be nearly equivalent to a binding curve for serpin-ligand 
interaction. This has been seen extensively with antithrombin-binding heparin 
pentasaccharide on the kinetics of antithrombin reaction with its target 
proteinases. 
More complex kinetic perturbations may also be studied. One common 
observation is that the ligand produces a bell shaped dependence of Kobs on 
ligand concentration in which the rate constant increases then plateaus at a 
peak, and then decreases. This effect is usually seen in the case of heparin, 
where the ligand binds both the serpin and proteinase. 443 45 The initial increase is 
the result of forma,tion of protein-ligand binary complex and when the ternary 
complex reacts with proteinase. The decrease at higher ligand concentrations 
reflects progressive blocking of ternary complex formation due to excess free 
ligand competing with the serpin-ligand complex for proteinase. 
In order to measure the specificity of the ligand serpin interaction, 
substitution of important residues on the serpin which interact with ligand or 
changing ligand structure may be done. In the case of glycosaminoglycans, the 
specificity was determined by immobilizing serpin on a gel while passing different 
structural variants of ligand through the gel. This procedure was done for low- 
affinity and high-affinity binding heparin. Here, the high-affinity heparin had a 
46-50 specific sequence giving it the high affinity binding. Mutagenesis is also a 
powerful tool for determining potential binding site on a serpin. In this approach, 
an expression system and a screening assay are required to identify any mutants 
with defective ligand binding but which are normally folded. Once the region has 
been identified, specific residues important in binding may be determined by 
mutagenesis and analysis of interaction. An exosite on antithrombin in the RCL 
region was shown to be quite important in factor Xa binding. 51.52 This procedure 
has helped to establish common binding sites on antithrombin, heparin cofactor 
II, PAI-I , and protease nexin-I in interaction with glyco~aminoglycans.~~ 
The most preferred method of mapping a ligand binding site on a serpin 
molecule and establishing whether a ligand has the capacity to induce 
conformational changes on the serpin is to solve the crystal structure of the 
serpin in the free, or unreacted state and complexed to ligand by X-ray 
diffraction. Here, ligand induced changes in antithrombin caused by heparin of 
both the binding site and the reactive center loop were easily evident by the free 
and complexed structures. In the case of protein C inhibitor in complex with two 
known ligands, retinoic acid and heparin, the structure of the complex has yet to 
be determined, although the free structure suggests binding sites of the hormone 
and heparin. The structure of the ternary bridging complex of heparin with the 
serpin and two proteinases, thrombin, and activated protein C, show that the 
serpin and proteinase would have to bind to opposite sides of a common site on 
heparin for the serpin RCL to interact with proteinase active site.54 
Heparin Pentasaccharide-Antithrombin 
Among the many ligands studied to date, several successfully inhibit 
serpins, and they are listed in the following table. Of particular interest is 
heparin, due to its wide range of targets within the serpin family, and which is a 
prime example of how ligand serpin interactions can yield therapeutic results. 
Heparin is a naturally occurring heterogeneous sugar polysaccharide found in the 
human body, and it plays a vital role in anticoagu~ation.~ The polymer form is 
comprised of 5 different monosaccharide units in varying amounts and is very 
acidic due to sulfate and carboxylic acid groups. Heparin pentasaccharide, 
which is the form of heparin used to bind to serpins, contains five unique sugar 
units denoted by DEFGH and has a molecular weight of about 1500 glmol. 
Heparin activity with antithrombin has proven to be especially important for 
therapeutic reasons. There are two distinct mechanisms for heparin-activated 
antithrombin inhibition of factor Xa and thrombin. The interaction of high-affinity 
heparin, or pentasaccharide H5, expels the partially inserted RCL residues 
altering the conformation of the PI-PI  0 reactive center and exposing an exosite 
in antithrombin (Fig. 5).55-59 This sequence of events is called the conformational 
activation of antithrombin. The altered RCL in heparin-antithrombin co-complex 
is easier recognized by factor Xa and this results in accelerated cleavage of the 
PI-PI0 bond and quick formation of the covalent inhibited complex (E*-AT* in 
Fig. 2). As a result of activation of antithrombin, factor Xa inhibition is increased 
sufficiently. Thrombin inhibition, in contrast, is accelerated only twofold through 
the conformational activation mechanism (see Fig. 4).51 The main effect of 
heparin in accelerating thrombin inhibition is due to a bridging mechanism. Tight 
binding of antithrombin to the H5 sequence in full length heparin is followed by 
the binding of thrombin to the same chain at non-specific sites to form an 
antithrombin-heparin-thrombin ternary complex (Fig. 5). Thrombin then diffuses 
along the polyanionic chain to encounter the inhibitor resulting in a -2,000-fold 
acceleration in inhibition under physiological conditions. A saccharide length of 
about 18 residues is needed to concurrently bind thrombin and antithrombin for 
the accelerated inhibition.60761 Thus, while sequence-specific H5 is necessary for 
tight binding of heparin chains, the H5 alone cannot potentiate antithrombin 
inhibition of thrombin. Here again the ligand in this case was reacted in the 
presence of both antithrombin and thrombin where heparin concentration was 
varied and a bell-shaped dependence of acceleration on the concentration of 
heparin chains, characteristic of a bridging mechanism, was observed. 
Figure 11: Heparin Pentasaccharide 
NHSO, OH NHSO; OSO, NHSO, 
Another serpin-ligand interaction of interest is that of plasminogen 
activator inhibitor-I (PAI-1) and vitronectin. PAI-1 is a member of a group of 
proteins known to inhibit plasminogen activators. When fibrinolysis occurs, 
tissue plasminogen activator (tPa) converts protein plasminogen into plasmin. 
As a result, plasmin then degrades fibrin along with providing for localized 
protease activity including ovulation, and cell differentiation. PAI-1 is the main 
inhibitor of tPA, and controls the production of plasmin, and as a result controls 
f i b r i n o ~ ~ s i s . ~ ~  Vitronectin is a large glycoprotein with a molecular weight of about 
75 kDa, and it also plays an important physiological role. It has been known to 
target antithrombin-thrombin complex, along with glycosaminoglycans including 
heparin playing a role in ~ o a ~ u l a t i o n . ~ ~ - ~ ~  It's major role is debatable but it is 
present in tissues and helps to promote cell adhesion. Interaction of vitronectin 
with PAI-1 is not known to inhibit the activity of active PAI-1, as vitronectin bound 
to PAI-1 is bound to the lower half of the serpin, in particular binding to residues 
on helix F, and strands 3 and 5 of P sheet A. 
Thyroxine-TBG; Corticosteroid-CBG 
Globulins including both thyroxine binding globulin (TBG), and 
corticosteroid binding globulin (CBG) bind to smaller organic molecules, and give 
us more insight into small molecule influence on serpin activity. Globulins play a 
major role in the immune system as they are carriers of antibodies. Thyroxine is 
a derivative of the amino acid tyrosine, and contains 4 iodine atoms. It is also the 
major hormone secreted by the thyroid gland. Nearly all of the thyroxine in the 
body is bound to TBG. TBG's most vital role in the body is as a carrier of 
thyroxine throughout the body so that it may help regulate metabolism and 
physical development. The structure of TBG and the binding site of thyroxine is 
still unknown to this date. Corticosteroids are a family of compounds including 
cortisol which is an adrenal hormone. There have been nearly a hundred 
synthetic derivatives of cortisol, which are being sold as drugs. Their main role is 
to block allergen and inflammatory activity by blocking prostoglandins, yielding 
powerful anti-inflammatory activity. The structure of CBG has been solved, 
although as is the case with TBG, the binding site of corticosteroids is unknown. 
Retinoic Acid-Protein C Inhibitor 
Retinoic acid interaction with Protein C inhibitor is also of interest, due to 
similarities in size of retinoic acid and the fluorophore ANS. Protein C inhibitor's 
physiological role is to inhibit activated protein C and thrombin through it's 
interaction with heparin, playing a dual, competing role in the anticoagulation 
pathway. 547 62 Heparin is believed to bind to protein C inhibitor at the H helix, 
which is at the backside of the molecule directly behind P sheet B. Retinoic acid 
is a organic derivative of vitamin A found in the epidermal and dermal layers of 
the skin, whose function it is to aid in the development and maintenance of bones 
and skin. The consequence of an interaction of retinoic acid with protein C 
inhibitor is unknown although it is thought to be a delivery protein in the same 
way that TBG delivers thyroxine throughout the body.62 Retinoic acid is 
hypothesized to bind in an area near helix A of protein C inhibitor, although the 
three dimensional structure of protein C inhibitor is not yet known. 
In 2001, a group of researchers documented an association between bis- 
ANS and PAI-1 .67 The structures of the conformations of PAI-1 show great 
variability between the active and the cleavedllatent forms. In the native 
structure, there is a large hydrophobic pocket located adjacent to strand 1 of P 
sheet A, and between both helix D and A, which is missing in the variants due to 
strand insertion. When the conformational variants were tested for fluorescent 
activity in the presence of bis-ANS, the native conformation displayed an 
intensity much greater than for cleaved, latent, or PAI-1 complexed to urokinase 
type plasminogen activator (uPA) as can be seen from graph 1 .67 Since the 
hydrophobic region is unique to the native form, and this area consists of mainly 
hydrophobic residues, it is hypothesized that bis-ANS binds in this particular 
region, which can be seen on Figure The residues implicated in binding to 
bis-ANS are shown in red, while those residues involved in vitronectin binding 
are shown in green. 
Figure 12: Fluorescence of 4 mM bis-ANS with selective conformations of PAI-1 
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Figure 13: Binding site of bis-ANS and vitronectin on PAI-1. 
Chapter 2: Methods 
Proteins and Stock Solutions 
Bovine al-antitrypsin (MW 57kDa) purchased from Sigma was in 
lyophilized powder form. 5 mg of antitrypsin was dissolved in 965 pL of 20 mM 
Tris-HCI buffer, pH 7.5, containing 100 mM NaCl (TBS) to give a stock solution of 
0.1 mM. Smaller volumes were aliquoted into 1.5 mL tubes at a concentration of 
10 pM and kept at 4°C for storage. Bovine trypsin (MW 25 kDa) was also 
purchased from Sigma. Twenty mg. of the trypsin stock was diluted with I mM 
HCI buffer to give a concentration of 43.5 pM in solution and was stored at -20°C. 
Human al-antichymotrypsin (ACT) was purchased in powder form from 
Calbiochem, while bovine a-chymotrypsin (CHY) was purchased from Sigma. 
One mg ACT was dissolved in 61 5 pL TBS, to give a stock concentration of 25 
pM, while 10 mg CHY was dissolved in 10 mL 1 mM HCI solution to give a stock 
concentration of 40 pM, which was subsequently diluted to desired 
concentrations for creating ACT-CHY complex. 
The substrate used for the CHY assay was Suc-AAPF-pNA (MW=625 
glmol), which was bought from Sigma in lyophilized powder form." Substrate is 
initially dissolved in 1 ml DMSO to 3 mM, which was diluted to 2 mM with 
additional TBS. On reaction with CHY the para-nitroaniline group is cleaved from 
peptide and displays a yellow color. This is measured by UVNis at 405 nm. 
The substrate used in the trypsin assay was Nu-benzoyl-L-arginine p- 
nitroanilide (L-BAPNA), which was purchased from Sigma in lyophilized powder 
form.69 L-BAPNA has a molecular weight of 435 Da. L-BAPNA substrate was 
dissolved in 20 mM Tris-HCI buffer, pH 7.5, containing 100 mM NaCl to give a 1 
mM stock solution. The 1 mM L-BAPNA was placed at 4°C fridge for storage. 
Km and Vmax of CHY and TRY 
The Km and Vmax determinations for Suc-AAPF-pNa reaction with CHY 
was carried out by reacting 10 nM CHY with various concentrations of substrate 
ranging from 0 to 100 pM in 1 mL TBS solution. The slopes of the reaction were 
recorded and the slope value were plotted against substrate concentrations. A 
curve fit based on the equation, y = (Vmax* x)l(Kd + x), was fit to the data points 
on the graph. 
The Km determination for the substrate was determined by aliquoting 10 
pL of the 43.5 pM stock solution into 900 pL TBS. 200 nM trypsin was titrated 
with L-BAPNA ranging from 0 to 500 p ~ . ~ '  The Km was determined by fitting the 
data to the previous equation. 
The stoichiometry o f  inhibition (SI) 
10 nM CHY was incubated with a range of concentrations of ACT from 0 
to 40 nM in 100 pL TBS overnight at 25°C. Next, the solution was diluted with 
850 pL of Tris-HCI buffer and 50 pM Suc-AAPF-pNA substrate was added to give 
a total volume of 1 mL. The absorbance was recorded for 3 min. at 405 nm. The 
values of the slope measurements were noted and a plot of slope versus 
[ACTIo/[CHYlo was prepared. From the plot, a linear regression of the data to 
obtain the point at which the line crosses the x axis gave the stoichiometry of 
inhibition. The reaction of trypsin with antitrypsin is monitored with L-BAPNA 
substrate. 200 nM trypsin is reacted with 0 to 500 nM antitrypsin in 1 ml TBS 
with 250 pM L-BAPNA. 
Preparation of cleaved serpin 
ACT 
Cleaved ACT was prepared by diluting stock ACT solution into 1 ml TBS 
to a concentration of I p ~ . ~ '  Human neutrophil elastase (HNE), purchased from 
Calbiochem, was added to give a final concentration of 20 nM or 1/50th the 
concentration of ACT. With the concentration of HNE being only a fraction of 
ACT, complex formation does not occur. The solution was incubated at 37°C for 
thirty minutes and every 5 minutes a sample was checked for residual CHY 
activity using hydrolysis of 50 pM Suc-AAPF-pNA substrate. The solution was 
then stored at -20°C, when the residual activity reached 3%, or 97% cleaved 
ACT was formed. 
AT 
10 pM native antitrypsin solution is diluted to 1 pM in 1 mL TBS. 40 pM 
porcine pancreatic elastase (PPE), purchased from Sigma, was added to give a 
final concentration of 1 pM. The ratio of serpin to proteinase was 1 :I. This 
solution was incubated at room temperature for 30 minutes. Samples were taken 
every 10 minutes to check for activity by adding trypsin and 250 pM L-BAPNA 
substrate, and after 90 minutes the activity of trypsin was -96%, suggesting 96% 
cleaved antitrypsin. 
Preparation of latent serpin 
ACT 
Formation of latent ACT was done by diluting a stock solution of native 
ACT to 1 pM in 1 mL TBS and then placed in 37°C warm water bath.72 The 
activity of CHY against ACT was repeatedly tested using hydrolysis of 50 pM 
Suc-AAPF-pNA substrate. In about 4 week's time, the enzymatic activity 
reduces to only about 5% suggesting -95% latent or polymerized form. 
AT 
The latent form of a,-antitrypsin was prepared as previously reported.73 
The 10 pM stock solution of antitrypsin was diluted 10 fold with TBS to yield a 
final concentration of 1 pM antitrypsin. The solution was incubated at 67°C for 
approximately 24 hrs. Samples were taken periodically to check for activity by 
adding trypsin and 250 pM L-BAPNA substrate, and after 24 hrs, antitrypsin 
activity was about 3%, suggesting 97% latent or polymerized form. Antitrypsin 
forms the latent complex at higher temperatures, but it is between 65-68"C, that 
formation of latent AT is maximized and polymerization is minimized.73 After 24 
hours, the latent AT solution was stored at -20°C until further analysis. 
Preparation of Serpin-Protease Complex 
Native ACT and CHY, each at a concentration of 1 pM, were mixed in a 1 
mL solution of TBS. The mixture was incubated for thirty minutes. Using the 
CHY assay previously discussed, the residual CHY activity was repeatedly 
measured. Following completion of reaction, the residual CHY activity is 
expected to be near zero. After verification that complex formation is complete, 
sample is stored at -20°C. 
Formation of AT-TRY complex was very similar to ACT-CHY complex. 
Equimolar ratios of native AT and TRY were mixed at 1 pM in 1 mL TBS. The 
mixture was incubated for 30 minutes, and assayed for activity using the TRY 
assay previously described. Residual TRY activity is expected to be near zero. 
After verification that complex formation was complete, sample was stored at - 
20°C. 
Preparation of stock solutions of fluorophores 
For this study, three hydrophobic aromatic fluorescent dyes have been 
chosen 2-anilinonaphthalene-6-sulfonic acid (2,6-ANS), 2-(p-toluidinyl) 
naphthalene-6- sulfonic acid (TNS), and (4,4'-dianilino-I ,I1-binaphthyl-5,5'- 
disulfonic acid (bis-ANS). ANS was purchased from Sigma as a lyophilized 
powder (>97% purity, HPLC). TNS was also purchases from Sigma in 
lyophilized powder form (>97% purity, HPLC), while bis-ANS was purchased 
from Molecular Probes in lyophilized form also (>95% purity, HPLC). 260 mg 
ANS was dissolved in 1 mL DMSO then diluted with 1.4 mL TBS to give a 34 mM 
stock solution. This solution was further diluted to give final concentration of 3.4 
mM. Twenty mg. of TNS was dissolved in 75/25 ethanol (mL)/DMSO (mL) 
mixture to 1 mL to give a 6.8 mM solution. Once fully dissolved, it was further 
diluted with 30 mL of TBS to give a 1.7 mM stock solution. The bis-ANS was 
previously diluted in 2 mL deionized water. The absorbance of the solution was 
detected and measured at 395 nm, and using Beer's Law, the concentration was 
measured to be about 2.4 mM, with extinction coefficient of 23,000 cm-' at 395 
nm.74 This solution was further diluted to 1.25 mM with 1.84 mL TBS. 
Determination of emission wavelength of fluorophores 
In a 3 mL acrylic cuvette, 25 pL of 3.4 mM ANS was pipetted into a 1 mL 
solution of TBS to give a 85 nM solution. The slits for the emission and excitation 
monochromators were .5 mm. The excitation wavelength was set at 404 nm, 
and emission was recorded from 425 to 600 nm. TNS spectrum analysis was 
performed in a manner similar to ANS. For TNS, the excitation wavelength was 
330 nm, while emission was recorded from 350 to 600 nm. The saturation 
concentration of TNS is about 20 pM. For bis-ANS the excitation wavelength 
was 425 nm, while emission is recorded from 440 to 600 nm. The maximum 
fluorescence was recorded for each fluorophore and used as emission 
wavelengths for titration procedures. 
Titration Procedures 
Three control samples were titrated: I )  fluorophore in buffer solution, 2) 
protease (chymotrypsinltrypsin) and fluorophore in buffer solution, and 3) porcine 
pancreatic elastase (PPE) and fluorophore in buffer solution. Using a PEG 
coated methacrylate cuvette, stock fluorophore 1 pL at a time up to 50 p M  was 
added to 1 . I  mL TBS, to measure the background fluorescence for all following 
titrations. The protease plus fluorophore titration was done to ensure no change 
in fluorescence occurs due to protease only. PPE and fluorophore control was 
measured due to the high concentration in solution during titration. For both 
protease and PPE 6.8 mL of 40 p M  protease was diluted into 1 .I mL TBS to 250 
nM. Fluorophore was added 1 pL at a time up to 50 pM. The results determined 
that protease and PPE had insignificant effect on the fluorescent activity of 
fluorophore. 
Gel Electrophoresis Analysis 
10% acrylamide gels were made with the following procedure: 2.5 mL of 
40% acrylamide, and 2.5 mL of pH 8.8 separating gel buffer were added to a 5.0 
mL water solution. Solution was degassed and 10 pL TEMED and 50 pL 
ammonium persulfate were added to mixture, mixed and added to gel plates. 
For stacking layer, 2.5 mL 40% acrylamide, 2.5 mL pH 6.8 stacking gel buffer 
were added to 5.0 mL water. Solution was degassed and 10 pL TEMED, and 50 
pL of ammonium persulfate were added to mixture, mixed and added to the 
separating layer. 
For samples, all conformational variants were at a concentration of 5 pM 
in 25 pL TBS. Six pL of 6X SDS buffer was added directly to stock, mixed and 
then placed in gel. The protein standard was purchased from Bio-Rad and was 
diluted 1.31 by adding 1 pL to 24 pL TBS, and 6 pL 6X SDS buffer. Gels were 
run until dye passed through gel. Gels were stained in Coomassie staining 
solution for two hours, and then destained in 881517% volume mixture of 
waterlmethanollacetic acid overnight. 
Modeling of Protein Surface 
The trypsin-antitrypsin complex protein structure (1 EOZ) was retrieved 
through PDB and analyzed using Sybyl. Formal charges were added using the 
Gasteiger-Huckel method. A surface scan was conducted using the fast 
Connolly method, and the hydrophobic potential was then mapped, where red 




There were three main objectives of this study: 
1) To determine whether the different conformational states of serpins can be 
differentiated with hydrophobic dyes using fluorescence spectroscopy. 
2) To determine whether a hydrophobic binding pocket exists in selected 
conformational forms of serpins. 
3) To determine whether the proteinase inhibitory activity of serpins can be 
modulated with hydrophobic fluorophores. 
The first objective is probably the most important because it attempts to 
develop an easy protocol for assessing the state of serpins. Knowing what 
form of serpin is in a given sample using fluorescence could be a good 
analytical tool compared to enzyme inhibition studies, due to its sensitivity 
and simplicity. Objectives 2 and 3 depend directly on the development of the 
first objective. The second objective points to a more fundamental principle. 
Many proteins have hydrophobic pockets in their complex 3D structure, and 
this study will help to determine if the same is true for serpin molecules. 
Along with this, the study will help to determine whether there is a specific 
hydrophobic pocket within the serpin molecule, which one or more of the 
fluorophores may bind to, and whether this pocket is conserved among the 
different conformational structures of serpins. While this study is being 
undertaken, favorable interactions will also be sought out as an increase in 
fluorescence intensity results from more hydrophobic character of interaction. 
This interaction will help to determine if a hydrophobic binding pocket exists, 
where it is, and if it is conserved among serpin subtypes such as 
antichymotrypsin and antitrypsin. Finally, objective 3 attempts to connect the 
hydrophobic pocket to serpin activity. Organic fluorophores will be exposed 
to native serpin during conversion into the latent form, to determine whether 
the fluorophores have any affect on the rate of this conversion, or modulation. 
Modulating the activity of serpin is a useful tool, as it might affect the in-vivo 
activity of serpins in humans. Many disease states involve the interactions of 
serpins with other molecules and with themselves, and manipulating their 
activity could possibility have therapeutic potential. 
Chapter 4: Results 
Background 
The initial goal of this work was to find a simple technique to distinguish 
the three conformational forms of a serpin and the serpin:proteinase complex. 
Serpins exist in a variety of conformations. A structural change within the serpin 
molecule affects the inhibitory activity of the ~ e r ~ i n . ~  These structural changes 
might be monitored by using the change in fluorescence of extrinsic fluorophores, 
which bind noncovalently to hydrophobic domains on the surface of protein 
molecules.73 Changes in the structure of a protein affect either quantum yield or 
affinity of these extrinsic fluorophores, which may be monitored. This has been 
shown in studies with ANS and ova~bumin.~~ Using mutant forms of ovalbumin 
that displayed loop insertion properties, ANS was found to bind primarily when 
loop insertion occurred.76 The binding of ANS resulted in an increase in 
fluorescence of the complex suggesting additional ANS molecules bound on loop 
insertion. Those mutants which do not loop insert showed a decrease in 
fluorescence signal, suggesting the release of ANS on proteolytic cleavage of the 
RCL. A similar study was also conducted by Egelund et al. in which the 
fluorescence decreases on proteolytic cleavage of the RCL of PAI-1 .66 Structural 
and binding studies were also conducted on PAI-1 binding to bis-ANS, a dimer of 
ANS. In addition to binding to bis-ANS, the fluorescence binding studies show 
binding to three different serpin variants along with urokinase type plasminogen 
activator. See Graph 1, Chapter 1 .I 
Another study proposed the existence of a hydrophobic binding region 
within a mutated form of PAI-1, and designed a ligand based on these findings7' 
A study conducted in 1998 by Lomas et al. described the formation of a 
canonical inhibitory conformation of a mutant of ant i t~y~s in .~ '  The study went 
further to reveal a difference in structure between the wild-type and mutant 
forms, and in particular a hydrophobic region within the wild-type between strand 
2 of p sheet A and helices D and E. The study suggested that the hydrophobic 
binding pocket may be exploited for creating ligands which do not allow the loop 
to insert. 
The purpose behind the use of al-antichymotrypsin and chymotrypsin as 
model system stems from it's importance in Alzheimer's disease, wherein 
amyloid beta (Ap) peptide occurs in insoluble plaques along with other 
molecules, including a-antichymotrypsin. In-vitro studies show that Ap binds to 
 ACT.^^ a,-Antitrypsin was also studied due to Lomas's work in detecting a 
potential hydrophobic binding pocket in ~ e r ~ i n s . ~ '  Binding studies conducted on 
the serpinslproteases will help to understand the characteristics of the variants 
and help to probe the differences among them. Using the hydrophobic 
fluorescent probes ANS, TNS, and bis-ANS binding studies will enable 
determination of favorable binding pockets within the structures. Using this 
knowledge, analogues of one or more of the fluorescent probes may be 
synthesized in order to target one or more of the protein structures. These 
analogues may then be used to design a small molecule marker, which may 
affect protease inhibitor. Furthermore, future molecular modeling studies will 
help to determine where on the protein these fluorescent molecules bind. 
Km and Vmax of (CHY-Suc-AAPF-pNA) and (TRY-L-BAPNA) Assays 
CHY-Suc-AAPF-pNA Assay 
Suc-AAPF-pNa is a blocked polypeptide ester with a phenylalanine side 
chain, which is a preferred substrate for chymotrypsin. 1.25 pL of 280 pM CHY 
was assayed for activity against different concentrations of Suc-AAPF-pNA 
substrate ranging from 0 to 100 pM, in a 1 mL TBS. The slopes were calculated, 
and the values shown on the following graph, where the x value is concentration 
of substrate and y value is the slope of the reaction curve. The Km value was 46 
4 pM, while Vmax was 108 * 5 mAbs/min. 
Figure 1. CHY Assay wlsubstrate 
10 nM CHY assay with Suc-AAPF-pNA 
TRY-L-BAPNA Assay 
Trypsin catalyzes hydrolysis of amides and esters of basic amino acids, 
such as the p-nitroanilide of benzoyl arginine (BAPNA). In the assay, 250 nM 
trypsin is reacted with various concentrations of 1 mM L-BAPNA ranging from 0 
to 500 yM in 1 mL TBS. The following graph was plotted, and x/y values are the 
same as for the CHY-substrate reaction. The Km values were 233 f 15 yM, 
while the Vmax was calculated to be 39 f 1 mAbs/min. 
Figure 2: TRY Assay wlsubstrate 
250 nM TRY assay with L-BAPNA 
L-BAPNA (pM) 




ACT activity was checked against CHY solution by taking 9 samples of 2.5 
pM ACT varying from 0 to 40 pL (0 to 100 nM) and mixing each with 8 pL 10 pM 
CHY, 50 pM Suc-AAPF-pNA and TBS to 1 mL. The change in absorbance is 
measured spectrophotometrically and the fractional chymotrypsin activity at each 
concentration of ACT is plotted vs. the nominal ratio of ACTICHY. A straight line 
regression slope is used to determine the molar ratio of ACT required to inhibit 
CHY. The linear decrease in CHY activity as ACT concentration increases is due 
to formation of inhibition complex. The stoichiometry of inhibition obtained form 
this plot is 1 :1.6. The stock solution of ACT is 63% active and in native form. 
Figure 3: S I  determination for ACT 
al -Antitrvpsin (AT) 
- 
The AT SI experiments are conducted in a similar manner to ACT as 
outlined in the methods section. AT activity against TRY solution was measured 
by taking 6 samples of 25 mM AT varying from 0 to 20 mL (0 to 450 nM) and 
mixing each with 5 mL 40 mM TRY, 200 mM L-BAPNA and TBS to 1 mL. The 
slope of the curves for trypsin catalyzed hydrolysis of L-BAPNA was measured 
spectrophotometrically, by measuring absorbance at 405 nm. In reaction with 
native AT, TRY was mixed into buffer solution, incubated overnight, diluted to 1 
mL, and then reacted with TRY substrate to check for residual activity. The SI for 
AT is 2.3:1, consistent with the supposed activity listed by Sigma. 
Figure 4: S I  determination for AT 
Preparation of Serpin:Protease complex 
ACT-CHY 
Activity of CHY decreased when equimolar concentrations (1 pM) of ACT 
and CHY are allowed to react for at least 10 minutes. Here, complex formation 
occurs and due to presence of CHY, no additional CHY is added. A sample of 
ACT:CHY was checked for inhibitor activity as a function of time, by taking a 10 
pL sample at various times and mixing it with 965 pL of TBS, and 50 pM Suc- 
AAPF-pNA, and following the increase in absorbance at 405 nm 
spectrophotometrically. The activity of CHY should decrease due to formation of 
ACT:CHY complex and after about 10 minutes, the activity of CHY leveled off. 
Thus, ACT and CHY at 1 pM were incubated for at least 10 minutes to ensure 
the formation of ACT-CHY complex in subsequent experiments. 
Figure 5: ACT-CHY reaction wlsubstrate 
ACT-CHY Assay with Suc-AAPF-pNa substrate 
Time (min) 
AT-TRY 
Initially, 1 pM of TRY solution was mixed with 1 pM active AT in 1 mL TBS 
for 15 minutes. A sample of the AT:TRY solution was checked for trypsin activity 
every 3 minutes by taking a 25 pL sample of 5pM AT:TRY, mixing it with 200 pM 
L-BAPNA and 865 pL of TBS and measuring the absorbance change at 405 nm 
spectrophotometrically. Activity against L-BAPNA substrate decreases 
exponentially to about 3% after 12 minutes. Thus, AT-TRY at 5 pM was 
incubated for at least 12 minutes to ensure formation of AT-TRY complex in 
subsequent experiments. 
Figure 6: AT-TRY reaction wlsubstrate 
AT-TRY assay with TRY substrate (L-BAPNA) 
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Preparation of Cleaved Serpin 
ACT 
One 1M cleaved ACT is prepared as previously described by digestion 
with HNE. The concentration of ACT in the preparation was 1 yM, while the 
concentration of HNE was 20 nM. Samples of cleaved ACT was checked for 
activity against CHY solution, by taking a 10 yL sample and mixing it with 1 yM 
CHY, 50 pM Suc-AAPF-pNA and 964 pL of TBS. This mixture was then 
monitored at 405 nm for CHY activity spectrophotometrically, and a linear 
increase in absorption indicating first order kinetics. Samples were taken every 
15 minutes until CHY activity was greater than 95%, indicating almost complete 
loss of ACT activity (98% cleaved ACT after 90 minutes). 




The cleaved conformation is formed using 1 pM PPE and incubating at 
room temperature with 1 pM AT as discussed in methods. Every 5 minutes a 
sample of AT was checked for activity against trypsin by hydrolysis of L-BAPNA, 
by taking a 25 pL sample of 5 pM cleaved AT and mixing it with 12.5 yL 10 yM 
TRY in 1 mM HCL, 200 pM L-BAPNA and 863 pL of TBS. The linear absorption 
change at 405 nm was measured spectrophotometrically. After about 30 minutes 
TRY activity was 96%, indicating 96% cleavage of antitrypsin. 
Figure 8: Cleaved AT reaction wlsubstrate 
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Preparation of Latent Serpin 
ACT 
Stock solution of 1 pM native ACT was placed in 1 mL TBS at 37°C in a 
warm water bath. Over 4 week's time, the solution was checked for activity by 
adding 10 nM with 50 pM Suc-AAPF-pNA in 1 mL TBS, and measuring 
absorbance at 405 nm using UVIVis. A linear increase was seen in each 
measurement, and this indicated that the reaction followed first order kinetics. 
After 4 weeks time, the solution showed nearly 95% residual CHY activity, 
indicating that only 5% of the ACT remained active. 




Using the 10 pM stock solution of antitrypsin, 500 pL was pipetted into a 
tube containing 1 mL of tris HCI pH 7.5 buffer to a concentration of 5 pM 
antitrypsin, which was then placed in hot water bath at 67°C for optimal latent 
formation. Periodically 25 pl samples were measured for TRY activity, by mixing 
it with 12.5 pL 10 pM TRY in 1 mM HCL, 200 pM L-BAPNA and 863 pL of TBS. 
This mixture was then analyzed for activity as described. Each measurement 
displayed linear increase in slope at 405 nm, characteristic of first order kinetics. 
After a period of 24 hours, the residual TRY activity was 95%, suggesting 95% 
latent antitrypsin. Polymer formation may have occurred even though reaction 
took place at 67"C, which is optimal for latent formation. 




The SI test was measured to ensure formation of cleaved ACT using 
concentration ratios ranging from 0 to 6: l  of cleaved ACT:CHY and extrapolating 
a linear slope to the x-axis. In particular, 10 nM of CHY solution is incubated with 
concentrations of cleaved ACT ranging from 0 to 60 nM in a 1 mL solution 
containing TBS and 50 pM Suc-AAPF-pNA. Hydrolysis was measured 
spectrophotometrically, and the CHY activity displayed as a function of the ratio 
of (cleaved ACT)/(CHY) concentrations. Even at a 6: l  ratio of cleaved ACT to 
CHY, activity is at or near 10O0/0. Using a linear regression line the slope of SI is 
positive, and the value of the SI of cleaved ACT: CHY reaction is undefined. 
Figure 10: SI Determination of Cleaved ACT 
Latent ACT 
To determine the latent ACT SI, samples of latent ACT at concentrations 
from 0-60 nm were incubated with 10 nM CHY in 1 mL TBS and 50 pM Suc- 
AAPF-pNA. The hydrolysis of substrate was measured 405 nm using UVIVis 
spectrophotometer, and the %CHY activity was plotted as a function of the ratio 
of (latent ACT)/(CHY) concentrations. The graph displays the ratio of latent ACT 
to CHY, and the slope decreases slightly giving an SI ratio of 65:l. Even at a 
molar ratio of 6:1, the activity of CHY was unaffected by latent ACT. The ACT 
has about 1.5% activity, a decrease of 60% from the native SI. 
Figure 11: S I  determination of Latent ACT 
ACT-CHY complex 
ACT-CHY complex was tested for its activity using CHY to ensure that all 
of the CHY was in complex. Again, the procedure was similar to other 
conformational variants of ACT. A 10 nM CHY solution was incubated with 
concentrations of ACT-CHY complex ranging from 0 to 60 nM in 1 mL TBS and 
CHY substrate, Suc-AAPF-pNA. The solution was then analyzed for hydrolysis 
activity at 405 nm using UV/Vis spectrophotometer, and the CHY activity was 
displayed as a function of the ratio of (ACT-CHY)/(CHY) concentrations. From 
the above graph, at high molar ratios of 6 to 1, the CHY activity is at or near 
100°/~. Any free CHY in solution would have displayed increased activity with 
increasing ratios. This is not the case as the activity remains near the control 
CHY activity. 
Figure 11: SI Determination of ACT-CHY complex 
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Cleaved AT 
Varying concentrations of cleaved AT ranging from 0 nM to 1.2 pM are 
mixed with 200 nM native TRY in 1 mL TBS, along with 200 yM L-BAPNA and 
the absorbance was measured at 405 nm. The SI of cleaved AT was 60:l. 
Figure 13: SI Determination of Cleaved AT 
Latent AT 
The AT SI experiments are conducted in a similar manner to ACT SI 
experiments as outlined in the methods section and the results are strikingly 
similar. Varying concentrations of latent AT ranging from 0 nM to 1.2 pM with 
200 nM native TRY in 1 mL TBS with 200 pM L-BAPNA were assayed. 
Absorbance change at 405 nm showed linear increase. The ratio of 
[latentAT]/[TRY] ranged from 0 to 6. At a ratio of 6 to 1, the TRY activity remains 
high, near 100%. The SI ratio for latent AT was about 65:1, indicating that 65 
moles of latent AT are required to inhibit 1 mole of native TRY. 
Figure 12: SI Determination of Latent AT 
AT-TRY complex 
Varying concentrations of AT-TRY complex ranging from 0 nM to 1.2 pM 
are mixed with 200 nM native TRY in 1 mL TBS, along with 200 pM L-BAPNA. 
The linear increase in absorbance was measured at 405 nm. The SI for AT-TRY 
was 56: 1 . 
Figure 14: SI Determination of AT-TRY complex 
SI of AT-TRY complex 
120 
UV and Fluorescence Spectrum 
The fluorescence spectra were measured before and after titrations for 
accuracy. It is important to choose a point where the absorbance values are 
quite low (at or near 0.1 mAbs1min) to ensure that the inner filter effect is not 
affecting titration studies. The following graph displays the emission spectrum. 
for ANS from which an excitation wavelength of 425 nm was chosen. The 
emission spectrum was recorded from 450 to 600 nm and an emission value of 
526 nm, which corresponds to a maxima peak. TNS was excited at 330 nm, and 
emission recorded from 365 to 500 nm. Bis-ANS was excited at 395 nm while 
emission was recorded from 425 to 500 nm. 
Figure 15 and 16: ANS 
UV spectrum of 60pM ANS in buffer 
2.0 
250 300 350 400 450 
Wavelength (nM) 
Fluorescence Spectrum of 60pM ANS; 
Excitation = 404 nM, Excitation = 440-600 nM 
0 
440 460 480 500 520 540 560 580 600 
Wavelength (nM) 
Figure 19 & 20. TNS 
UV Spectrum of 20 pM TNS in buffer 
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Fluorescence Emission Spectra of 20 p.M TNS; 
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Figure 21 & 22. bis-ANS 
UV Spectrum of bis-ANS at 20pM in buffer with 
a,-ACT conformers 
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conformers; Excitation = 395 nm Emission = 450 to 550 nm 
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SDS-PAGE 
SDS allows proteins to be separated according to their molecular weight. 
The latent and native forms of serpins should have a very similar molecular 
weight, whilelthe cleaved form will be slightly less due to missing strands at the C 
terminus after cleavage of the PI -PI '  scissile bond. SDS is a highly negatively 
charged molecule, which denatures the protein by coating the surface with 
multiple negative charges, and therefore creates a uniform shape for all proteins 
that it comes in contact with. Using an 10% acrylamide gel and low molecular 
weight protein standards bought from Bio Rad, gel electrophoresis can be done 
with known molecular weights. The protein standards include proteins ranging 
from 15-95 kDa, covering the desired range of 50-70 kDa. For all conformations 
of antichymotrypsin, 25 pI of 5 pM sample is mixed with 5 pl SDS and placed in 
gels after heating. The following gel shows all conformations of 
antichymotrypsin, along with protein standards. 
Figure 23: SDS PAGE Gel of Serpins 
The protein standards include albumin at a MW of 66,000 and is the 
second from top mark. Using this as a guide, the different conformations of ACT 
can be seen right across from it in rows 2-5. Antichymotrypsin has a molecular 
weight range from 65 to 68 kDa, so it should appear close to albumin standard, 
and does so. Cleaved ACT is lower than either the native or latent forms, due to 
loss of 3 kDa in cleavage. Antitrypsin shows up at about the 55 kDa range, and 
both latent and native conformations are as predicted. Cleaved antitrypsin 
should show up at a slightly lower molecular weight, yet it shows up at the same 
level of both the latent and native versions. More importantly, the complexed 
versions of both ACT:CHY and AT:TRY fail to show up on any of the geldudies 
conducted. Unfortunately, substrate activity is the only measure of determining 
the presence of complex. 
Titrations 
Introduction 
ANS, TNS, and bis-ANS are fluorophores that bind to hydrophobic 
pockets of proteins. The fluorophores fluoresce, and when bound to proteins the 
intensity of fluorescence light emitted changes. Any variation in the fluorescence 
arises from a change in the environment of the fluorophore. This change is 
generally an increase on association and a decrease on dissociation of the 
fluorophore. This change may be interpreted as monitoring the binding. 
In this particular study ANS, TNS, and bis-ANS have been used to titrate 
all four conformations of ACT and AT. In order to accurately measure any 
association that a fluorophore may have with either molecule, a background 
study must be conducted every time the machine is used to check for lamp 
stability, to subtract from the titrations, and most importantly to simply make sure 
the fluorophore is active, stable and working properly. All titrations were 
conducted in 1100 pL Tris-HCL pH 7.5, with fluorophore stock solution added in 
1 and 2 pL increments while measuring the emission. Fluorescence data is 
interpreted simply as the difference of intensity of each titration minus the initial 
reading. The data is converted to percentage change in fluorescence data to 
make the readings more useful and to standardize between experiments. Over 
time, the lamp used to conduct runs weakens so therefore the raw data results 
may actually vary by a great deal. The curve fit used is the KA equation as given, 
F = ((JDFma*) 10.5) * ( ( [LI ,  +KD + [Rl,) - (([Ll ,  + KD + [R1J2 - pmxTo), 
where f is fit to y. Here KD = [R]o[L]o/[RL], where [RIo is the receptor (serpin, 
serpin: protease) concentration in this case is 250 nM and [LIo is the ligand 
concentration which changes for each titration point. 
ANS, TNS, and bis-ANS backgrounds 
The fluorophore is added in small increment to 1 100 pLTBS. Mixing 
homogeneity is important for an accurate measurement. There should be a linear 
increase in emission with increasing fluorophore concentration. 
Native ACT 
Results of native ACT binding experiments with ANS are displayed on the 
following graph (Fig. 24). The graph shows that the native ACT fluorescence 
intensity increases by about 100% in reaction with ANS with a AFmax value at 95 
+ 2%. KD values for the association are 7.5 + 0.8 pM suggesting that ANS binds 
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with quite high affinity. At a value of about 7.5 pM, the native form binds with 
about twice the affinity of the complex and nearly 8 times greater affinity than the 
latent form. This value is lower than the latent form and complex while greater 
than the cleaved form. The AFmax and KD values show that native ACT binds 
tighter than latent and cleaved ACT, while the AFmax values are also higher than 
for the cleaved and latent form. 
Native ACT binding experiments with TNS display greater affinity of the 
fluorophore for the native protein as is the pattern with all serpin variants. The KD 
values are 12.1 + 1.0 pM, similar to all other serpin variants in reaction with TNS. 
Native ACT has the RCL exposed while both latent and cleaved ACT have loop 
inserted into P-sheet A. This difference in structure may explain the differences 
in the KD and AFmax. 
Cleaved ACT 
Cleaved ACT is taken from stock and placed in 11 00 pL TBS. Titration 
studies are carried out using 1 pL ANS aliquots at a time reaching a maximum 
concentration of ANS at 80 pM, while protein concentration is maintained at 250 
nM. It is important to note that there is a residue of human neutrophil elastase 
within the cleaved ACT sample, but since the sample ratio is 1 :I00 of ACT to 
HNE, a concentration of 2.5 nM is negligible in the solution of target serpin and 
ligand. The results in figure 24 show a small relative increase in the fluorescence 
of ANS. The KD value for ACT cleaved-ANS complex was found to be 9.1 + 3.0 
pM by fitting the data to the quadratic binding equation. The AFmax values are 
8.8 k 0.8%. Cleaved ACT shows very little change from the background in 
fluorescence (about 9%). 
Binding studies with TNS are conducted in a similar manner (figure 25). 
Since TNS is a more sensitive fluorophore than ANS, titrations are conducted 1 
pL at a time to a final concentration of 20 pM in a protein solution of 250nM. 
Results with TNS are differentiated from ANS by a greater increase in relative 
fluorescence. The point of saturation is at a concentration 4 times less than that 
of ACT. Although the KD values are almost identical to the ANS reaction at 9.1 k 
1.5 pM, the AFmax values are more than 10 times greater at 109 k 8%. 
Results from the bis-ANS saturation show the same trend as that for ANS 
and TNS. Fluorescence intensity measurements show that the cleaved ACT 
shows the lowest change of all the serpin variants. The KD values for cleaved 
ACT were recorded but are quite suspect due to irregularity in the fluorescence 
results. There was quite a bit of variation in the three experiments. The KD from 
averaging the three experiments come out to 31 k .03 pM, which is 3 times 
higher than either ANS or TNS. AFmax values were found to be 166 k 1 %. 
Latent ACT 
Structurally the latent form differs from the cleaved by an extra loop which 
returns to the top of the serpin. In addition cleaved ACT has an extra strand in P 
sheet C. These two structural differences might cause variations in fluorescence 
with different fluorophores. 
Fluorescence binding experiments with ANS show some interesting 
results. The KD values for latent ACT are 51.2 & 6.6 pM, which is about 4 times 
higher than the other three variants. This leads to some interesting questions 
about the structure of the latent form. The uniqueness of its structure must play 
some part in the weak binding of ANS. Latent ACT has an extra loop return 
which probably affects the ability of ANS to bind to the scaffold of ACT as it does 
on the native and cleaved versions. The AFmax is quite high at 328 k 19%, an 
increase of over 3 times the initial background study. 
Latent ACT displayed the highest relative change in fluorescence with 
TNS. In terms of fluorescence TNS would serve as the best option for identifying 
the latent ACT form by fluorescence methods. KD values are quite high 
according to the curve fit equation, which means that although TNS does not 
bind with the same affinity to the latent form as the other variants, the AFmax for 
latent ACT is higher with TNS than the other fluorophores. The change in 
fluorescence is greater than 700%. KD values for reaction with TNS are 12.9 & 
0.6 pM, which are in line with affinities of other serpin variants of ACT for TNS. 
The AFmax values for this reaction are 765 & 15%, a value nearly 2 times greater 
than the next highest value. This suggests that the latent form has more 
hydrophobic pockets to which TNS associates than other variants. 
Bis-ANS shows the second highest change in fluorescence. Its relative 
change in fluorescence is nearly 400 times the initial fluorescence reading. The 
KD values are 10.7 k 4.2 pM, displaying an affinity lower than either the native 
form or the complex. The AFmax values are 494 & I I %, a 500% increase from 
the initial background studies. This value pales in comparison to the complex 
reaction with bis-ANS, but it is nearly equivalent to the native from. From these 
experiments, it is safe to assume that both TNS and bis-ANS are suitable 
fluorophores for detecting the presence of the latent form. 
ACT-CHY complex 
The results of relative fluorescence intensity change show that the 
complex displays the greatest increase of all four structures on binding 
fluorophore. The fluorescence intensity change of nearly 33% relative to the two 
native active protein structures, and is not due to binding to CHY. ANS titrations 
with a-chymotrypsin showed minimal fluorescence binding. 
In binding experiments conducted in the presence of ANS fluorophore, the 
ACT-CHY complex displayed a KD value of 15.4 +_ 1.9 pM, a value only slightly 
different from the other serpin variants. The AFmax value for this reaction was 
286 k 4%, which is on the higher end of the spectrum, although lower than the 
latent form. 
In reaction with TNS, the results were similar to the native form. The KD 
values for complex reaction with TNS are 11.2 & 1.4 pM, while the AFmax values 
are 369 + 22%. The AFmax values for both the TNS and ANS reaction show that 
complex interaction with these fluorophores consistently creates a noticeable 
change in the intensity of fluorescence. 
Complex binding with bis-ANS gave a KD value of 4.5 + 0.8 pM, lower than 
complex reaction with other fluorophores, making bis-ANS the most sensitive 
fluorophore in reaction with ACT-CHY complex (figure 26). The AFmax value at 
3569 + 249% shows the greatest increase in intensity. In fact the AFmax value is 
nearly 36 times greater than the background, a noticeable difference in intensity. 
Bis-ANS is clearly a good candidate for further study and analysis in its 
interaction with the ACT-CHY complex. 
Figure 24 
ANS titration of ACT- Native, Cleaved, Latent 
and ACT:CHY complex 
Latent ACT 
V Cleaved ACT 
V ACT-CHY 
Serpin Conformation KD (PM) AFmax (%I 
ACTL 51.2 k 6.6 328 + 19 
ACTc 9.1 + 3.0 N/A 
ACTN 7.5 + 0.8 95k2 
ACT-CHY 15.4 + 0.9 286 k 4 
Figure 25 
TNS titration of ACT- Native, Cleaved, Latent 
and ACT:CHY complex 
8 Cleaved ACT 
Latent ACT 
Serpin Conformation KD (PM) AFmax (%I 
ACTL 12.9 + 0.6 765 k 17 
ACTc 9.1 * 1.5 109f 8 
ACTN 12.1 k 1.0 339f 15 
ACT-CHY 11.2 + 1.4 369 f 20 
Figure 26 
B-ANS titration of ACT- Native, Cleaved, Latent 
and ACT:CHY 
0 2 4 6 8 10 12 
B-ANS (pM) Native ACT 
Cleaved ACT 
Latent ACT 
V ACT:CHY 1 
Serpin Conformation KD (PM) AFmax (%) 
ACTL 10.7 +_ 4.2 494 & 1 1  
ACTc .31 _+ 0.3 166f1 
ACTN 2.5 & 0.4 547 f 29 
ACT-CHY 4.5 0.8 3569 + 248 
Native AT 
Native AT shares a structural conformation similar to native ACT in the 
fact that it has an exposed RCL. The RCL of native AT differs from native ACT 
by four amino acids, and its P I  group is methionine as opposed to arginine for 
native ACT. As a result of this similarity, binding studies should show a pattern 
similar to ACT, as is seen for the cleaved and latent forms. 
Binding studies conducted with ANS reveal that the KD value is 10.4 + 0.7 
pM and the AFmax value is 185 k 3%. Native antitrypsin shows greater affinity 
for ANS than either the latent or complex form. In reaction with both TNS and 
bis-ANS, native AT has higher AFmax values than the cleaved form pointing to 
greater association of fluorophores to the native form versus the cleaved. KD 
values calculated for TNS and bis-ANS are 9.3 k 0.6 pM, and 2.8 + 0.3 pM, while 
AFmax values are 976 + 26%, and 573 + 17%. Affinity values point to the fact 
that bis-ANS is the best fluorophore for binding to the native form, while AFmax 
values point to TNS as being the best in determining increase in fluorescence. 
Cleaved AT 
Cleaved AT is formed by reaction with porcine pancreatic elastase (PPE). 
The procedure calls for a equimolar ratio of elastase to serpin thus there is an 
appreciable amount of PPE remaining in the reaction thus pancreatic elastase is 
also titrated to correct for background. 
Results of the cleaved AT binding to ANS is shown on figure 27. Cleaved 
AT shows the lowest relative increase in fluorescence intensity as also noted with 
cleaved ACT. The KD value was found to be 10.3 + 0.9 pM, while the AFmax 
value was 153 + 4%. 
Both TNS and bis-ANS binding results for cleaved AT are similar to results 
for ANS in that relative fluorescence changes are the lowest of all the 
conformations. The KD values for TNS bound to cleaved AT are 11.6 2 1.4 pM, 
while AFmax values are 743 + 45%. For bis-ANS the results are 1.2 + 0.1 pM for 
KD, while the AFmax is 401 + 6%. There is not much difference in affinity 
between ANS and TNS, while bis-ANS at I .2 pM binds at about 10 times less 
concentration. 
Latent AT 
Binding studies to ANS, TNS, and bis-ANS are seen on figures 23-25. 
Latent AT shows some similarity to latent ACT in its high KD values. According to 
the curve fit results, bis-ANS would be the best candidate for binding studies with 
latent AT. The results for binding to ANS are 17.3 + 0.8 pM for KD, while the 
AFmax values are 247 + 4. TNS give a KD value of 7.9 2 0.5 pM and AFmax 
values of 686 + 18%. In reaction with bis-ANS, the values are 3.6 2 0.4 pM for 
KD and 869 + 32% for AFmax. Bis-ANS shows the greatest change in 
fluorescence according to the graphs, and the AFmax values are highest for bis- 
ANS, while KD values suggest that TNS has the greatest affinity for latent AT of 
the fluorophores studied. 
AT-TRY complex 
The AT-TRY complex shows similar results in that AFmax values for the 
complex are higher for all three fluorophores bound to it. KD values for ANS, 
TNS, and bis-ANS are 21.3 5 0.6 yM, 10.5 + 0.4 pM, 1.6 + 0.1 pM respectively. 
Here, it is quite evident that bis-ANS shows the greatest binding affinity to the 
complex. Although AT-TRY shows a high increase in affinity with bis-ANS at 
about 10 fold, complex association with TNS is 26 fold over initial readings, as 
evident by AFmax values for the complex. The AFmax values are 61 8 5 7,2634 
+ 46, 910 + 13 for ANS, TNS and bis-ANS respectively. Here it is important to 
point out that the complex shows AFmax values higher than any other form of 
serpin whereas in the ACT system the latent form had slightly higher AFmax 
values in association with both ANS and TNS, than the complex. It is difficult to 
pinpoint exactly why the complexes display such differences except to point out 
that that the two serpin:proteinase complexes are structurally different and these 
differences point to variability in exosite binding structures, where the 
fluorophores may bind. 
Figure 27 
ANS titration of AT- Native, Cleaved, Latent 
and AT:TRY complex 
ANS(PM) 
@ Cleaved AT 
Latent AT 
V AT:TRY 
Serpin Conformation KD (PM) AFmax 
ATL 17.3 * 0.8 247 A 4 
ATc 10.3 + 0.9 1532 4 
ATN 10.4 0.7 185k3 
AT-TRY 21.3 A 0.6 618+7 
Figure 28 
TNS titration of AT- Native, Cleaved, Latent 




Serpin Conformation KD (PM) AFmax (%I 
ATL 7.9 & 0.5 686 + 18 
ATc 11.6 * 1.4 743 + 45 
ATN 9.3 * 0.6 976 & 26 
AT-TRY 10.5 * 0.4 2634 46 
Figure 29 
B-ANS titration of AT- Native, Cleaved, Latent 
and AT:TRY complex 
Native AT 
AT:TRY 
V Cleaved AT 
Serpin Conformation KD (PM) AFmax (%) 
ATL 3.6 + 0.4 869 + 32 
ATc 1.2 + 0.1 401 f 6 
ATN 2.8 * 0.3 573 * 17 
AT-TRY 1.6 kO.1 910 * 13 
Overall Results 
KD values of the serpin variants indicate some important things. If the 
ligand is unchanged while the receptor environment is varied, then the results 
may be analyzed in terms of the most favorable receptor. Table 30 shows that 
there seems to be no consistent pattern. ANS binds all serpin variants with 
about the same affinity, as is also the case for TNS and bis-ANS. Looking down 
each column where the serpin variant is kept constant and the ligand changes, 
one can notice a trend. The KD values decrease as the ligand changes from 
ANS to TNS to bis-ANS. 
Figure 30. Overall KD values 
Figure 31: Overall AFmax values 
I I I I I I I I 
TNS 1765k171 1 0 9 k 8  1339k151 369+20 16865181 743k45  1976*2612634k46 
The AFmax values are more useful. Across each row where the ligand 
environment is kept constant and the receptor is variable, few patterns are 
discernible. First, the cleaved form of the serpin shows the least change in 
AFmax values suggesting that the hydrophobic binding pocket within this 
structure does not associate well with all three ligands. Both latent and complex 
forms of the serpin show consistently higher AFmax values than either the native 
or cleaved. This may be interpreted as both variants associating to a higher 
degree than the native and cleaved variants of the serpins, and pointing to a 
binding site with greater hydrophobic character or more number of hydrophobic 
sites. More importantly, differentiation between the conformational variants is 
possible due to the differences in AFmax values. Within each column 
conclusions are more difficult to make. On average, both bis-ANS and TNS 
associate to a greater degree than ANSI due to higher AFmax values. 
Ligand 
ANS 
Modulation of Enzyme Activity 
It's known that pH, concentration of ions, and temperature have an 
adverse affect on enzyme activity. For example it is known that chymotrypsin 
ACTN 
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and trypsin perform optimally at pH 8.5, and at 37°C. The presence of other 
molecules on enzyme activity is seen in the human body and this keeps 
enzymatic activity under physiological control. The purpose of performing a 
modulation study with organochemical ligands and serpin molecules is to deduce 
whether these molecules affect serpin activity. If these ligands do affect activity, 
then this knowledge can be used to further study the interaction. More 
importantly, effects on enzyme activity may be exploited for medicinal purposes, 
especially in disease states where serpin molecules are involved. 
The particular study that was undertaken to check for modulation of serpin 
activity by bis-ANS involved setting up the experimental procedure for generating 
the latent form of serpin molecules. 100 p1 of 2 pM antichymotrypsin is allowed 
to incubate with 10 pM bis-ANS. A similar sample of antichymotrypsin by itself is 
incubated as a control measure. 10 p1 samples are measured at 0, 1, 3, 5, 8 and 
24 hours to measure for residual chymotrypsin activity. The results of this 
experiment are displayed on the following graph (figure 32). The graph shows 
that there is little if any influence of bis-ANS on the activity of native 
antichymotrypsin conversion to the latent form. At all the time points the residual 
chymotrypsin activity of both the sample with bis-ANS and the sample wlbis-ANS 
are within 5% of each other. From the results of the graph one can conclude that 
bis-ANS will have an inconsequential effect on the activity of antichymotrypsin. 
Figure 32 
Modulation of 2 pM ACT using 10 pM B-ANS 
Time (hr) 
Hydrophobic Binding Domains in Serpin Conformations 
After determining our results, the next step is to model the complex, and 
look for potential hydrophobic pockets which may exist within the external 3- 
dimensional structure. The following figure (33) shows the scaffold of antitrypsin- 
trypsin complex (1 EOZ), and below it is a topological surface rendering of the 
complex, using SYBYL. Looking at the hydrophobic potential surface scan 
(figure 34), the colors at the top or brown areas represent the most hydrophobic 
potential, whereas the colors at the bottom represent hydrophilic potential. Just 
from viewing the face of 50% of the molecule there are several potential pockets 
where bis-ANS may bind. There are two pockets to the right of strands 1 and 2 
of 0 sheet A, and to the left of helix E which are similar to pockets implicated in 
vitronectin:PAl-1 potential binding. 
Figure 33: 3-D structure of AT-TRY complex 
tcl 
Figure 34: Hydrophobic potential map of AT-TRY complex 
Chapter 5: Conclusions 
Returning to our objectives we may be able to put in perspective the 
results from our study. The first objective deals with differentiation of the 
conformations of serpins using fluorescence spectroscopy. From the results the 
first objective has been met, and this is due to the unique values for each of the 
conformations when fluorophore is bound. 
Both the antitrypsin and antichymotrypsin systems display some common 
and unique results. Both the AT and ACT show that the TNS and bis-ANS 
fluorophore are overall more sensitive in detecting the presence of both serpin 
systems, while ANS is the least sensitive, and this is apparent from looking at the 
AFmax values. The KD values do not show any consistent pattern amongst the 
respective serpin systems. 
In terms of unique results, bis-ANS reaction with ACT has the greatest 
affinity of the three fluorophores for ACT. In particular, bis-ANS showed elevated 
association to the ACT-CHY complex, while bis-ANS did not show similar results 
for the AT system. For the AT system, the AT-TRY complex displayed elevated 
association with TNS fluorophore. This difference in results can be exploited 
through detailed study of the external structure of both complexes. ACT and AT 
share 45% homology, therefore differences in complex structure are likely. 
From the binding studies of the ACT system there are a few clear 
conclusions. Both TNS and bis-ANS give higher AFmax values than ANS. 
Concentrations used for ANS are about 10 times lower for titrations. Bis-ANS 
gives significantly higher AFmax values for the ACT: CHY than the other 
conformations, while also exhibiting relatively low KD values averaging 5 pM. 
From the binding studies of the AT system a few conclusions may also be made. 
Both TNS and bis-ANS also give higher AFmax values than ANS. KD values for 
the bis-ANS titration are relatively low when compared to other dyes. Bis-ANS 
has greater affinity for the AT system than does either TNS or ANS. AFmax 
values for TNS titration of AT: TRY complex are significantly higher than other 
structural conformers of AT. 
Fluorescent dyes bind tightly to hydrophobic pockets within the protein 
structure. Bis ANS displays an increase in fluorescence 36 times higher for 
ACT:CHY complex than for buffer solution alone, and TNS 27 times higher for 
the AT:TRY than buffer alone. With the data given, designing analogues to probe 
the structure of the serpin: protease complex to determine the degree of 
interaction and ability to control the kinetics of this interaction are possible. 
The second objective, modulation of serpin activity by fluorophores, 
showed that exposing bis-ANS to native ACT during it's conversion to latent ACT 
had no significant effect on its activity. Therefore, it is concluded that 
fluorophores, in particular bis-ANS, does not modulate the transition between 
native and latent serpin structures. 
The third objective, to determine whether there is a conserved binding site 
on serpins, was addressed and reveals numerous hydrophobic pockets which 
may bind small organic fluorophores such as ANS. Determining whether binding 
occurs to a specific pocket might prove difficult, due to differences in serpin 
structure and the large number of potential binding pockets. In order to study 
this, further tests must be conducted including modeling and mapping of the 
external structure of serpins. 
As a final note, formation of the conformations yielded some problems. 
First, the formation of latent conformation was verified using assay, and 
procedure which limits polymer formation, but the possibility of polymers forming 
in solution still remains. The gel electrophoresis studies show presence of the 
latent confirmation, but this could just as easily be polymers, as they are known 
to form from ionic bonding, which would be broken in the presence of SDS. The 
second issue has to do with the results of the gel electrophoresis experiments. 
Unfortunately, formation of complex was not verifiable through this method, 
although procedures for complex formation were adhered to, and assay 
experiments validated complex formation. 
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